Difference between revisions of "PRAL"

From LncRNAWiki
Jump to: navigation, search
(Function)
Line 4: Line 4:
  
 
LncRNA-PRAL<ref name="ref1" />
 
LncRNA-PRAL<ref name="ref1" />
 +
 
===Characteristics===
 
===Characteristics===
LncRNA-PRAL is transcribed with a poly A1 tail, diffusely distributed both in the nucleus and cytoplasm, and localizes to both cytoplasmic and nuclear regions <ref name="ref1" />.
+
LncRNA-PRAL localizes on chromosome 17p13.1, and is transcribed with a poly A tail <ref name="ref1" />.
most of the sequence of the lncRNAPRAL overlaps in antisense with the 3' untranslated region of XAF1 protein-coding gene, which is known to regulate apoptosis<ref name="ref1" />.
+
Most of the sequence of the lncRNA-PRAL overlaps in antisense with the 3' untranslated region of XAF1 protein-coding gene, which is known to regulate apoptosis<ref name="ref1" />.
  
 
===Cellular Localization===
 
===Cellular Localization===
LncRNA-PRAL (p53 regulation-associated lncRNA)localizes on chromosome 17p13.1<ref name="ref1" />.
+
LncRNA-PRAL is diffusely distributed both in the nucleus and cytoplasm, and localizes to both cytoplasmic and nuclear regions <ref name="ref1" />.
 
 
===Regulation===
 
  
 +
===Function===
 +
Somatic copy number variation of lncRNA-PRAL is associated with hepatocellular carcinoma (HCC) growth and lncRNA-PRAL may serve as a potential target for antitumor therapy <ref name="ref1" />. LncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53 <ref name="ref1" />. The three stem-loop motifs at the 5' end of lncRNA-PRAL facilitates the combination of HSP90 and p53 and thus competitively inhibites MDM2-dependent p53 ubiquitination, resulting in enhanced p53 stability <ref name="ref1" />.
  
===Function===
+
PRAL might be a tumor suppressor in lung cancer <ref name="ref2" />. The transcript level of PRAL is decreased in lung cancer in vivo and in vitro, and overexpression of PRAL inhibites cell proliferation by upregulating the expression of P53 <ref name="ref2" />.
LncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53.
 
The three stem-loop motifs at the 50 end of lncRNA-PRAL facilitated the combination of HSP90 and p53 and thus competitively inhibited MDM2-dependent p53 ubiquitination, resulting in enhanced p53 stability<ref name="ref1" />.
 
  
Transfection of PRAL plasmid inhibits cell proliferation in NCI-H929 and A549 cells and promotes the transcription of P53<ref name="ref2" />.
+
===Expression===
 +
Expression level of PRAL is decreased in lung cancer <ref name="ref2" />.
  
 
===Diseases===
 
===Diseases===
 
*Hepatocellular Carcinoma<ref name="ref1" />
 
*Hepatocellular Carcinoma<ref name="ref1" />
 
*Lung Cancer<ref name="ref2" />
 
*Lung Cancer<ref name="ref2" />
 
  
 
==Labs working on this lncRNA==
 
==Labs working on this lncRNA==
Line 31: Line 30:
 
*Department of Surgery, Xi'an Red Cross Hospital, Affiliated to School of Medicine, Xi'an Jiao Tong University, Xi'an, Shanxi, China(mainland).
 
*Department of Surgery, Xi'an Red Cross Hospital, Affiliated to School of Medicine, Xi'an Jiao Tong University, Xi'an, Shanxi, China(mainland).
 
*Maternal and Child Care Service Center of Changan District, Xi'an, Shanxi, China (mainland)<ref name="ref2" />.
 
*Maternal and Child Care Service Center of Changan District, Xi'an, Shanxi, China (mainland)<ref name="ref2" />.
 
  
 
==References==
 
==References==
 
<references>
 
<references>
<ref name="ref1">
+
<ref name="ref1"> Zhou CC, Yang F, Yuan SX, Ma JZ, Liu F, Yuan JH, Bi FR, Lin KY, Yin JH, Cao GW, Zhou WP, Wang F, Sun SH. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology. 2016 Mar;63(3):850-63. </ref>
Zhou CC, Yang F, Yuan SX, Ma JZ, Liu F, Yuan JH, Bi FR, Lin KY, Yin JH, Cao
+
<ref name="ref2"> Su P, Wang F, Qi B, Wang T, Zhang S. P53 Regulation-Association Long Non-Coding RNA (LncRNA PRAL) Inhibits Cell Proliferation by Regulation of P53 in Human Lung Cancer. Med Sci Monit. 2017 Apr 11;23:1751-1758.</ref>
GW, Zhou WP, Wang F, Sun SH. Systemic genome screening identifies the outcome
 
associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma.
 
Hepatology. 2016 Mar;63(3):850-63.
 
</ref>
 
<ref name="ref2">
 
Su P, Wang F, Qi B, Wang T, Zhang S. P53 Regulation-Association Long
 
Non-Coding RNA (LncRNA PRAL) Inhibits Cell Proliferation by Regulation of P53 in  
 
Human Lung Cancer. Med Sci Monit. 2017 Apr 11;23:1751-1758.
 
</ref>
 
 
</references>
 
</references>

Revision as of 09:44, 26 July 2017

Annotated Information

Name

PRAL:p53 regulation associated lncRNA

LncRNA-PRAL[1]

Characteristics

LncRNA-PRAL localizes on chromosome 17p13.1, and is transcribed with a poly A tail [1]. Most of the sequence of the lncRNA-PRAL overlaps in antisense with the 3' untranslated region of XAF1 protein-coding gene, which is known to regulate apoptosis[1].

Cellular Localization

LncRNA-PRAL is diffusely distributed both in the nucleus and cytoplasm, and localizes to both cytoplasmic and nuclear regions [1].

Function

Somatic copy number variation of lncRNA-PRAL is associated with hepatocellular carcinoma (HCC) growth and lncRNA-PRAL may serve as a potential target for antitumor therapy [1]. LncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53 [1]. The three stem-loop motifs at the 5' end of lncRNA-PRAL facilitates the combination of HSP90 and p53 and thus competitively inhibites MDM2-dependent p53 ubiquitination, resulting in enhanced p53 stability [1].

PRAL might be a tumor suppressor in lung cancer [2]. The transcript level of PRAL is decreased in lung cancer in vivo and in vitro, and overexpression of PRAL inhibites cell proliferation by upregulating the expression of P53 [2].

Expression

Expression level of PRAL is decreased in lung cancer [2].

Diseases

  • Hepatocellular Carcinoma[1]
  • Lung Cancer[2]

Labs working on this lncRNA

  • Department of Medical Genetics, Second Military Medical University, Shanghai, 200433, China.
  • The Third Department of Hepatic Surgery, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, 200433, China.
  • Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.[1]
  • Department of Surgery, Xi'an Red Cross Hospital, Affiliated to School of Medicine, Xi'an Jiao Tong University, Xi'an, Shanxi, China(mainland).
  • Maternal and Child Care Service Center of Changan District, Xi'an, Shanxi, China (mainland)[2].

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Zhou CC, Yang F, Yuan SX, Ma JZ, Liu F, Yuan JH, Bi FR, Lin KY, Yin JH, Cao GW, Zhou WP, Wang F, Sun SH. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology. 2016 Mar;63(3):850-63.
  2. 2.0 2.1 2.2 2.3 2.4 Su P, Wang F, Qi B, Wang T, Zhang S. P53 Regulation-Association Long Non-Coding RNA (LncRNA PRAL) Inhibits Cell Proliferation by Regulation of P53 in Human Lung Cancer. Med Sci Monit. 2017 Apr 11;23:1751-1758.